Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Not Yet Opened 04-01 16:00:00 EDT

71.78

+0.14

+0.20%

High72.78	Low71.64	Vol984.49M
Open71.64	D1 Closing71.64	Amplitude1.59%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O17.91B	T/O Rate--	Tradable Shares0.00
P/B6.682266	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":71.78392,"timestamp":1775073599999,"preClose":71.64154,"halted":0,"volume":984487982,"delay":0,"changeRate":0.001987,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0.14238,"latestTime":"04-01 16:00:00 EDT","open":71.64188,"high":72.780136,"low":71.64178,"amount":17907870436.441334,"amplitude":0.01589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775116800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.682266,"peRate":-172.314087,"turnoverRate":0.028818,"increases":337,"decrements":169,"flats":10,"marketCap":1850308529529.5938,"floatMarketCap":1654372514478.125},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2624529152","title":"Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529152","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624529152?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:05","pubTimestamp":1775095557,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on April 1, 2026. Director Fairmount Funds Management LLC has significant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-zenas-biopharmas-future-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-zenas-biopharmas-future-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624529137","title":"Top Executive’s Bold Stock Move Shakes Up Cytokinetics Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529137","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624529137?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:04","pubTimestamp":1775095477,"startTime":"0","endTime":"0","summary":"New insider activity at Cytokinetics ( ($CYTK) ) has taken place on April 1, 2026. Cytokinetics has seen notable insider activity as President & CE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-bold-stock-move-shakes-up-cytokinetics-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-bold-stock-move-shakes-up-cytokinetics-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CYTK","BK4211","ISBC","BK4585","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108555307","title":"Zai Lab Shares Climb Over 4% Following Global Clinical Partnership with Amgen for Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1108555307","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108555307?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:52","pubTimestamp":1775094739,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) rose more than 4% in Hong Kong trading, with the stock up 4.22% to HK$15.79 by the time of writing, as turnover reached HK$98.01 million. The increase follows an announcement on April...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","BK1574","LU2089984988.USD","LU2242646821.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1057294990.SGD","BK4585","BK4533","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU2488822045.USD","BK4599","LU0889565916.HKD","09688","BK4534","BK1588","BK4526","BK4566","LU0868494617.USD","VXUS","LU0058720904.USD","SG9999001440.SGD","LU0320765992.SGD","BK4139","BK4531","BK4581","BK4548","BK4588","LU2112291526.USD","AMGN","LU2468319806.SGD","IE00B4R5TH58.HKD","ZLAB","BK1161","IE00B2B36J28.USD","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","LU0109394709.USD","LU0289739699.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624161526","title":"BRIEF-Celldex Announces Pricing Of $300 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2624161526","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624161526?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:48","pubTimestamp":1775094534,"startTime":"0","endTime":"0","summary":"BRIEF-Celldex Announces Pricing Of $300 Million Public Offering Of Common StockApril 1 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX ANNOUNCES PRICING OF $300 MILLION PUBLIC OFFERING OF COMMON S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUABMFXPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624261665","title":"Celldex Therapeutics Inc - Prices Public Offering of 10,345,000 Shares at $29.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2624261665","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624261665?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:48","pubTimestamp":1775094499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUABMFXPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624525054","title":"AnaptysBio director John P. Schmid disposes shares worth $1.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624525054","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624525054?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:28","pubTimestamp":1775093338,"startTime":"0","endTime":"0","summary":"AnaptysBio director John P. Schmid sold 20,645 shares on March 30, 2026.Shares were sold at weighted-average prices ranging from $55.71 to $57.4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3Yh8py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AnaptysBio director John P. Schmid disposes shares worth $1.1 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624253925","title":"Quince Therapeutics Delays Annual 10-K Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624253925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624253925?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:43","pubTimestamp":1775090632,"startTime":"0","endTime":"0","summary":"Quince Therapeutics ( ($QNCX) ) has released a notification of late filing. Quince Therapeutics, Inc. has notified regulators that it will delay fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528036","title":"CytomX Therapeutics Signals Progress in Varseta-M Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528036","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528036?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:12","pubTimestamp":1775088769,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc. (($CTMX)) has held its Q4 earnings call. Read on for the main highlights of the call. CytomX Therapeutics’ latest earnings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-signals-progress-in-varseta-m-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-signals-progress-in-varseta-m-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4097","PRGS","CTMX","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528035","title":"Rigel Pharmaceuticals Balances Breakout Growth With Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528035?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:12","pubTimestamp":1775088727,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals (($RIGL)) has held its Q4 earnings call. Read on for the main highlights of the call. Rigel Pharmaceuticals’ latest earnings ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rigel-pharmaceuticals-balances-breakout-growth-with-caution?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rigel-pharmaceuticals-balances-breakout-growth-with-caution?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624852865","title":"Inovio plans underwritten public offering of common stock with Series A and B warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2624852865","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624852865?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:05","pubTimestamp":1775088323,"startTime":"0","endTime":"0","summary":"Inovio launched an underwritten public offering of common stock with Series A warrants and Series B warrants.All securities in offering will be sold by Inovio.Underwriter received 30-day option to buy up to 15% more shares and warrants.Pricing and size will depend on market conditions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL4Jzf0l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4127","LU0053671581.USD","BK4583","PIPR","BK4139","INO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528695","title":"Inovio Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528695?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:05","pubTimestamp":1775088300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA2LCTYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","BK4583","INO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528360","title":"Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528360","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528360?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:00","pubTimestamp":1775088056,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics director Sabar Karimah Es sold 115,000 shares in transactions dated March 31, 2026 and April 1, 2026.Sales were executed at weighted average prices of $30.17 and $31.03 per share.Es reported 0 shares owned following the transactions.Filing also showed option exercises totaling 115,000 shares at $4.86 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL6nJyfX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528313","title":"Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528313","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528313?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:00","pubTimestamp":1775088055,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics EVP, General Counsel Karen Krasney sold 25,000 shares on March 31, 2026 at weighted average price of $30.12.Krasney exercised stock options for 24,000 shares on March 31, 2026 at prices ranging from $1.39 to $3.74.Directly held common stock position fell to 30,547 shares following reported transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5qjCpB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528314","title":"Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528314","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528314?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:00","pubTimestamp":1775088049,"startTime":"0","endTime":"0","summary":"Capricor CFO Anthony Bergmann reported sale of 25,000 shares on March 31.Disposition priced at USD 30.13 per share on weighted-average basis.Filing also showed exercise of options for 25,000 shares at USD 3.18 per share.Holdings in common stock fell to 8,223 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9QDQps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528536","title":"CERo Therapeutics Delays 2025 Annual Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528536?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:55","pubTimestamp":1775087747,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings ( ($CERO) ) has released a notification of late filing. CERo Therapeutics Holdings, Inc. has notified investors that it ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cero-therapeutics-delays-2025-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cero-therapeutics-delays-2025-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624407775","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2624407775","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624407775?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:50","pubTimestamp":1775087400,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nAQN2LSVU0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528365","title":"A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528365","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528365?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:28","pubTimestamp":1775086120,"startTime":"0","endTime":"0","summary":"Recent analyst commentary around pharmacy benefit manager reform, a rebate-free model and a leadership change has put Cigna Group (CI) back in focus for investors watching how regulatory shifts shape earnings visibility.\nSee our latest analysis for Cigna Group.\nThose regulatory updates and the CEO transition are playing out against a softer trading backdrop, with a 30 day share price return of an 8.09% decline and a 1 year total shareholder return of a 17.76% loss suggesting momentum has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-after-pbm-reform-progress-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-after-pbm-reform-progress-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PBM","PRGS","IE00BSNM7G36.USD","BK4196","CI","LU0289739699.SGD","LU1059921491.USD","BK4139","BK4588","BK4097","LU2065732104.USD","LU0058720904.USD","LU0868494617.USD","LU1261432733.SGD","IE00B19Z3581.USD","BK4585","IE00B19Z3B42.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547703","title":"Kymera COO Jeremy G Chadwick disposes of USD 1.9 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547703","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547703?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:00","pubTimestamp":1775084450,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick cut direct holdings to 61,202 shares.Chadwick sold 22,240 shares on March 31 and April 1 at prices around $85.38 to $86.05.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL27Tv6f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kymera COO Jeremy G Chadwick disposes of USD 1.9 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624154770","title":"Kymera director Elena Ridloff disposes of USD 1.3 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624154770","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624154770?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:00","pubTimestamp":1775084449,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics director Elena Ridloff sold 13,000 shares on March 31-April 1.Sales were priced at about $85.37 per share on March 31.Additional shares sold April 1 were priced at about $85.19-$86.05 per share.Ridloff’s direct holdings fell to 0 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4nXBBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624254727","title":"Alkermes EVP R&D, CMO Craig Hopkinson disposes of shares worth $0.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624254727","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624254727?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084375,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson sold 9,000 ordinary shares on April 1, 2026 at a weighted average price of USD 35.51.Directly held ordinary shares totaled 85,389 following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5BDdSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, CMO Craig Hopkinson disposes of shares worth $0.3 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.052},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0282},{"period":"1year","weight":0.1626},{"period":"ytd","weight":-0.0463}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}